动脉粥样硬化性心血管疾病和衰弱的研究进展与临床启示  

Research Advances and Clinical Implications of Atherosclerotic Cardiovascular Diseases and Frailty

作　　者：陈偲 王丽[1] 

机构地区：[1]重庆医科大学附属第二医院老年医学科,重庆

出　　处：《临床医学进展》2025年第1期974-980,共7页Advances in Clinical Medicine

摘　　要：伴随全球人口老龄化进程的加速,衰弱与动脉粥样硬化性心血管疾病(ASCVD)的发病率呈现出明显的上升趋势,二者之间存在着错综复杂的双向关联,并且共享着许多相同的危险因素以及潜在的生物学机制。衰弱已被明确认定为心血管疾病患者极为关键的独立预后指标,它不仅深刻影响着心血管疾病的一级和二级预防策略的制定与实施,同时也对这些患者能否顺利被纳入关键临床试验以及接受高级心脏干预措施等构成了实质性的障碍。在当今的医学领域,动脉粥样硬化性心血管疾病与衰弱已然成为备受瞩目的两大健康焦点问题。本文通过检索相关国内外文献,对衰弱与ASCVD的相关研究做一综述。With the acceleration of the global population aging process, the incidences of frailty and atherosclerotic cardiovascular disease (ASCVD) have shown a significant upward trend. There exists a complex bidirectional relationship between them, sharing numerous common risk factors and underlying biological mechanisms. Frailty has been clearly identified as a crucial independent prognostic indicator for patients with cardiovascular diseases. It not only profoundly influences the formulation and implementation of primary and secondary prevention strategies for cardiovascular diseases but also poses a substantial obstacle to the inclusion of these patients in key clinical trials and their access to advanced cardiac intervention measures. In the current medical field, atherosclerotic cardiovascular disease and frailty have become two prominent health focus issues. By extensively retrieving relevant domestic and foreign literature, this article comprehensively and systematically reviews the latest research findings on frailty and ASCVD.

关 键 词：衰弱 心血管疾病 动脉硬化 衰老 衰弱评估 

分 类 号：R54[医药卫生—心血管疾病]